"Ann Intern Med"[journal] 检索结果

821. Web Exclusive. Annals Video Summary - Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction.

来源: Ann Intern Med. 2025年178卷2期e2403635VS页

822. Web Exclusive. Annals Graphic Medicine - 2 Face Comics Presents: Art Is the Best Medicine.

作者: Raphel Awa.
来源: Ann Intern Med. 2025年178卷1期eG240016页

823. Letter From the American College of Physicians to the U.S. Presidential Transition Team.

作者: Isaac O Opole.; .
来源: Ann Intern Med. 2025年178卷2期285-287页

824. Census Tract Rurality, Predominant Race and Ethnicity, and Distance to Lung Cancer Screening Facilities : An Ecological Study.

作者: Solmaz Amiri.;Candice L Wilshire.;Clemma Jacobsen Muller.;Cole Allick.;Allison C Welch.;Gary Ferguson.;Dedra Buchwald.;Jed A Gorden.
来源: Ann Intern Med. 2025年178卷2期177-186页

The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) for adults who meet specific age and smoking history criteria.

825. Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction : A Systematic Review and Meta-analysis.

作者: Joel C Boggan.;Spoorthi Sankineni.;Paul A Dennis.;Dazhe Chen.;Tina Wong Sledge.;David Halpern.;Sharron Rushton.;John W Williams.;Tatyana Der.;Amir Alishahi Tabriz.;Adelaide M Gordon.;Morgan Jacobs.;Nathan A Boucher.;Maria Colandrea.;Anastasia-Stefania Alexopoulos.;Joanne Roman Jones.;Nina Leflore-Lloyd.;Sarah Cantrell.;Karen M Goldstein.;Jennifer M Gierisch.
来源: Ann Intern Med. 2025年178卷2期229-240页

Postdischarge contacts (PDCs) after hospitalization are common practice, but their effectiveness in reducing use of acute care after discharge remains unclear.

826. Metabolic Dysfunction-Associated Steatotic Liver Disease.

作者: Sajjadh M J Ali.;Michelle Lai.
来源: Ann Intern Med. 2025年178卷1期ITC1-ITC16页

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in the United States. It is characterized by steatosis in the liver and is potentially reversible. Risk factors include obesity, type 2 mellitus, and other metabolic disorders. Metabolic dysfunction-associated steatohepatitis (MASH), a more severe form of MASLD, puts patients at risk for cirrhosis, liver decompensation, and liver cancer. Diet, exercise, and weight loss are the cornerstones of management. Although only 1 medication has been approved for treatment of MASH, other pharmacotherapies and surgeries that aid weight loss and optimize metabolic risk factors can be used. Early diagnosis and intervention are important to prevent progression to cirrhosis and its complications, including cancer.

827. Web Exclusive. Annals On Call - Diagnostic Reasoning Part 1.

作者: Robert M Centor.;Jerome P Kassirer.
来源: Ann Intern Med. 2025年178卷1期e2404114OC页

828. Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis : A Target Trial Emulation.

作者: Soichiro Masuda.;Toshiki Fukasawa.;Shuichi Matsuda.;Koji Kawakami.
来源: Ann Intern Med. 2025年178卷2期167-176页

Dialysis patients have high rates of fracture morbidity, but evidence on optimal management strategies for osteoporosis is scarce.

829. Web Exclusive. Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.

来源: Ann Intern Med. 2025年178卷2期e2403525VS页

830. In subclinical AF, apixaban vs. aspirin reduced stroke or systemic embolism at 3.5 y, regardless of duration of recent subclinical AF episodes.

作者: Eric R Bates.; .
来源: Ann Intern Med. 2025年178卷1期JC7页

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

831. Assessing the Risk for Falls in Older Adults After Initiating Gabapentin Versus Duloxetine.

作者: Alexander Chaitoff.;Rishi J Desai.;Niteesh K Choudhry.;Katharina T Jungo.;Nancy Haff.;Julie C Lauffenburger.
来源: Ann Intern Med. 2025年178卷2期187-198页

The evidence informing the harms of gabapentin use are at risk of bias from comparing users with nonusers.

832. In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA1c but increased severe hypoglycemia at 26 wk.

作者: Felipe Larios.;Michael R Gionfriddo.;Victor M Montori.; .
来源: Ann Intern Med. 2025年178卷1期JC11页

Endocrinology: [Formula: see text].

833. Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.

来源: Ann Intern Med. 2025年178卷2期I19页

834. In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 mo.

作者: Mitra Chitsazan.;Harriette G C Van Spall.; .
来源: Ann Intern Med. 2025年178卷1期JC2页

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

835. In HFpEF, semaglutide reduced a composite of worsening HF or CV death.

作者: Steven Ho Man Lam.;Gregory Y H Lip.; .
来源: Ann Intern Med. 2025年178卷1期JC4页

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

836. In long-term users of benzodiazepine receptor agonists, direct-to-patient interventions vs. usual care reduced use at 6 mo.

作者: Sean P Haley.; .
来源: Ann Intern Med. 2025年178卷1期JC9页

GIM/FP/GP: [Formula: see text] Geriatrics: [Formula: see text].

837. In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 mo.

作者: Raúl Moreno.; .
来源: Ann Intern Med. 2025年178卷1期JC6页

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

838. In adults aged ≥75 y with NSTEMI, an invasive vs. conservative strategy did not improve a composite outcome at a median 4.1 y.

作者: Michael W Rich.; .
来源: Ann Intern Med. 2025年178卷1期JC5页

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Geriatrics: [Formula: see text].

839. In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA1c at 52 wk.

作者: Felipe Larios.;Michael R Gionfriddo.;Victor M Montori.; .
来源: Ann Intern Med. 2025年178卷1期JC10页

GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].

840. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

作者: Areesha Moiz.;Kristian B Filion.;Helia Toutounchi.;Michael A Tsoukas.;Oriana H Y Yu.;Tricia M Peters.;Mark J Eisenberg.
来源: Ann Intern Med. 2025年178卷2期199-217页

Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes.

结果排序

文献格式

出版时间

出版类型

出版语言

821. Web Exclusive. Annals Video Summary - Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction.

822. Web Exclusive. Annals Graphic Medicine - 2 Face Comics Presents: Art Is the Best Medicine.

823. Letter From the American College of Physicians to the U.S. Presidential Transition Team.

824. Census Tract Rurality, Predominant Race and Ethnicity, and Distance to Lung Cancer Screening Facilities : An Ecological Study.

825. Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction : A Systematic Review and Meta-analysis.

826. Metabolic Dysfunction-Associated Steatotic Liver Disease.

827. Web Exclusive. Annals On Call - Diagnostic Reasoning Part 1.

828. Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis : A Target Trial Emulation.

829. Web Exclusive. Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.

830. In subclinical AF, apixaban vs. aspirin reduced stroke or systemic embolism at 3.5 y, regardless of duration of recent subclinical AF episodes.

831. Assessing the Risk for Falls in Older Adults After Initiating Gabapentin Versus Duloxetine.

832. In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA1c but increased severe hypoglycemia at 26 wk.

833. Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.

834. In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 mo.

835. In HFpEF, semaglutide reduced a composite of worsening HF or CV death.

836. In long-term users of benzodiazepine receptor agonists, direct-to-patient interventions vs. usual care reduced use at 6 mo.

837. In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 mo.

838. In adults aged ≥75 y with NSTEMI, an invasive vs. conservative strategy did not improve a composite outcome at a median 4.1 y.

839. In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA1c at 52 wk.

840. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.